Lanham O'Dell & Company, Inc. Ocugen, Inc. Transaction History
Lanham O'Dell & Company, Inc.
- $165 Million
- Q1 2025
A detailed history of Lanham O'Dell & Company, Inc. transactions in Ocugen, Inc. stock. As of the latest transaction made, Lanham O'Dell & Company, Inc. holds 116,000 shares of OCGN stock, worth $82,360. This represents 0.05% of its overall portfolio holdings.
Number of Shares
116,000Holding current value
$82,360% of portfolio
0.05%Shares
4 transactions
Others Institutions Holding OCGN
# of Institutions
117Shares Held
75MCall Options Held
200KPut Options Held
151K-
Black Rock Inc. New York, NY17.9MShares$12.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.7MShares$11.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$4.89 Million0.0% of portfolio
-
State Street Corp Boston, MA5.93MShares$4.21 Million0.0% of portfolio
-
Ubs Group Ag4.37MShares$3.1 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $154M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...